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Abstract
Grade IV glioblastoma is characterized by increased kinase activity of epidermal growth factor 
receptor (EGFR); however, EGFR kinase inhibitors have failed to improve survival in individuals 
with this cancer because resistance to these drugs often develops. We showed that tumor necrosis 
factor–α (TNFα) produced in the glioblastoma microenvironment activated atypical protein kinase 
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C (aPKC), thereby producing resistance to EGFR kinase inhibitors. Additionally, we identified 
that aPKC was required both for paracrine TNFα-dependent activation of the transcription factor 
nuclear factor κB (NF-κB) and for tumor cell–intrinsic receptor tyrosine kinase signaling. 
Targeting aPKC decreased tumor growth in mouse models of glioblastoma, including models of 
EGFR kinase inhibitor–resistant glioblastoma. Furthermore, aPKC abundance and activity were 
increased in human glioblastoma tumor cells, and high aPKC abundance correlated with poor 
prognosis. Thus, targeting aPKC might provide an improved molecular approach for glioblastoma 
therapy.
INTRODUCTION
World Health Organization (WHO)–designated grade IV glioma or glioblastoma is a 
frequently occurring brain tumor with poor prognosis (1). The relative survival estimate for 
glioblastoma indicates that only 4.46% of patients diagnosed between 1995 and 2006 
survived 5 years after the initial diagnosis (2, 3). Although strategies to improve the 
currently dismal survival of glioblastoma patients primarily involve identifying and 
targeting oncogenic signaling pathways (1, 4–6), the therapeutic success of such approaches, 
including inhibition of the kinase activity of epidermal growth factor receptor (EGFR), has 
been limited (7). The activation of additional receptor tyrosine kinases (RTKs) and/or 
downstream tumor-intrinsic mutations can provide oncogenic stimuli to glioblastoma tumor 
cells and accounts for EGFR kinase inhibitor resistance (7, 8). Identifying and targeting such 
pathways can improve therapeutic efficacy, although such efforts may require 
simultaneously disabling multiple, parallel oncogenic signals. The serine-threonine kinase 
atypical protein kinase C (aPKC) is activated downstream of multiple RTKs (9–11). aPKC 
regulates neural progenitor cell proliferation and migration during the embryonic 
development of the spinal cord (12). Abnormal activation and altered intracellular 
localization of aPKC in avian neuroepithelia results in increased proliferation, abnormal 
migration, and rosette-like structures reminiscent of brain tumors (12). Therefore, we 
hypothesized that the abnormal or unscheduled activation of the developmentally important 
aPKC signaling pathway may be associated with glioblastoma progression and that aPKC 
inhibition may be a potential therapeutic strategy in glioblastoma.
RESULTS
aPKC abundance inversely correlates with glioblastoma survival and targeting aPKC 
reduces tumor progression in a mouse model of glioblastoma that is resistant to EGFR 
kinase inhibitors
We examined the abundance of aPKC in human nontumor brain and glioblastoma tissue. 
Immunohistochemical staining of nontumor brain tissue sections revealed low aPKC 
staining in the brain parenchyma (Fig. 1A). Neurons showed some cytoplasmic staining (fig. 
S1A), and oligodendrocytes occasionally showed trace staining. In contrast, glioblastoma 
tumor cells showed strong aPKC staining (Fig. 1, B and C). The distribution of staining was 
consistent across variable histologic patterns that define glioblastoma, such as 
pseudopalisading necrosis (Fig. 1C and fig. S1B), areas of microvascular proliferation (fig. 
S1C), infiltrative single cells, clusters, and confluent cell sheets. Next, we stained tissue 
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microarrays consisting of 330 glioblastoma cases. The aPKC staining was validated using 
both negative and positive staining on control cores of nonneoplastic cortical gray matter, 
white matter, cerebellum, placenta, testis, lung, liver, kidney, and tonsil within each tissue 
microarray. Within most but not all glioblastoma cores, tumor cells showed increased aPKC 
staining relative to nontumor cells. We compared aPKC staining in tumor cells to that of 
adjacent nontumor cells within each core and assigned a numerical score of 0, 1, 2, or 3 
representing negative, weak positive, intermediate positive, or bright staining, respectively. 
Most glioblastomas were aPKC-positive, with approximately equal fractions being aPKC 
bright, intermediate positive, or weak positive. These findings suggest that aPKC abundance 
tends to be high in glioblastomas, although the abundance of aPKC between individual 
glioblastomas varied and glioblastomas could be stratified on the basis of aPKC intensity 
(Fig. 1D). Furthermore, staining a smaller set of glioblastoma samples (44 cases) with the 
aPKC activation–specific, phosphoThr410/403 antibody suggested that not only total protein 
abundance but also aPKC activity was high in glioblastomas (Fig. 1, E and F). The range of 
staining intensity for phosphorylated aPKC compared to that for total aPKC was somewhat 
reduced, which could be because the phosphorylation-specific antibodies have a lower 
affinity than the total aPKC antibody for their substrates.
To further examine the clinical relevance of the intensity of aPKC staining in glioblastoma, 
we compared the association between aPKC immunoreactivity and survival. In a tissue 
microarray annotated with the survival data of the patients, 7 cases had no detectable aPKC 
staining, 17 cases had weak positive staining, and 20 cases showed bright aPKC staining. 
Statistical analyses demonstrated that the bright aPKC staining cases (median survival of 
176.5 days) had a significantly shorter median survival than the aPKC-negative or weak 
positive cases (median survival of 413 and 532 days, respectively) (Fig. 1G). Statistically 
significant differences were not detected between the survival rates of the lower categories 
of aPKC intensity. Survival did not correlate with gender and age in the sampled population. 
Together, these results demonstrate that aPKC abundance is increased in glioblastoma and 
that there is a strong negative correlation between aPKC protein abundance and survival.
To assess the role of aPKC in glioblastoma progression in vivo, we performed orthotopic 
xenograft experiments in non-obese diabetic/severe combined immunodeficient (NOD/
SCID) mice using U87 glioblastoma cells that express the constitutively active EGFRvIII 
mutation (U87/EGFRvIII cells) and U87/EGFRvIII cells in which both aPKC genes 
(PRKCZ and PRKCI) were silenced by a virally delivered short hairpin RNA (shRNA) (fig. 
S2A, table S2). Mice with orthotopic xenografts derived from U87/EGFRvIII cells with 
aPKC silencing had a longer median survival of 35 days, compared to the median survival 
of 11 days in mice with xenografts derived from control U87/EGFRvIII cells (Fig. 1H). 
Histopathological examination revealed that the tumors derived from U87/EGFRvIII cells 
expressing aPKC shRNA were significantly smaller than those derived from control U87/
EGFRvIII cells (Fig. 1I). Subsequently, we tested the efficacy of a small-molecule, 
benzimidazole adenosine triphosphate–competitive aPKC inhibitor PZ09 (13) in inhibiting 
tumor growth in vivo. These experiments revealed that inhibition of aPKC reduced tumor 
volume by 64.68 ± 9.23% after 7 days of treatment (Fig. 1J).
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Next, we tested the efficacy of aPKC inhibition in patient-derived, EGFR kinase inhibitor–
resistant, orthotopic xenografts. Patient-derived GBM6 xenograft cells retain the clinically 
relevant biochemical characteristics of human glioblastoma, including EGFR amplification 
and the EGFRvIII mutation (14, 15), and are insensitive to the EGFR kinase inhibitor 
erlotinib (16). PZ09 effectively decreased aPKC activity in GBM6 cells in culture (fig. 
S2E), and the acute inhibition of aPKC by PZ09 significantly reduced tumor volume in 
orthotopic xenografts by 84.06 ± 6.27% (Fig. 1K). In summary, intracranial glioblastoma 
growth, including that of glioblastoma resistant to EGFR inhibition, was effectively 
suppressed by aPKC inhibition.
aPKC functions downstream of RTKs in glioblastoma
Both wild-type EGFR and EGFRvIII are frequently present in glioblastoma (17) and both 
EGFR subtypes were detected in GBM6 cells, although EGFRvIII appeared to be the 
predominant subtype according to reverse transcription polymerase chain reaction (RT-
PCR) (fig. S3A). EGF stimulation activated aPKC in serum-starved GBM6 cells (Fig. 2A). 
Moreover, PZ09 treatment of GBM6 cells reduced EGF-induced expression of CD44, 
MMP9, and VCAM (Fig. 2B). Similarly, aPKC was phosphorylated when U251 cells stably 
expressing EGFR (U251/EGFR cells) were stimulated with EGF (Fig. 2C). aPKC silencing 
by short interfering RNA (siRNA) in U251/EGFR cells (fig. S2B, table S2) also reduced the 
expression of EGF-induced genes (Fig. 2D). EGFR was phosphorylated with faster kinetics 
than aPKC in both GBM6 and U251/EGFR cells (fig. S3, B and C), suggesting the 
possibility that aPKC is an indirect downstream target of EGFR. These results indicate that 
aPKC mediates EGFR signaling in glioblastoma. Our findings are consistent with the 
reported function of this kinase downstream of EGFR family in tumor progression in breast 
cancer and squamous cell carcinomas of head and neck (10, 18). aPKC was also activated 
downstream of activated Ras, phosphatidylinositol 3-kinase (PI3K), and Src (Fig. 2E). 
EGFR kinase inhibitor resistance is often associated with PTEN mutations (7). Furthermore, 
EGFR kinase inhibitors can be rendered ineffective by the simultaneous activation of 
multiple RTKs in glioblastoma (19) or the activation of compensatory pathways, such as the 
transcriptional activation of Met in mouse models of EGFR kinase inhibitor–resistant 
glioblastoma (20). Because aPKC functions further downstream of PTEN (21–23) and 
participates in signaling downstream of Ras and Src (24–26), aPKC may function 
downstream of multiple RTKs and therefore may be a more attractive target than EGFR in 
glioblastoma.
Tumor necrosis factor–α functions as a paracrine oncogenic signal in glioblastoma
Paracrine factors and the induction of EGFR-independent, parallel oncogenic signals 
through non–cell-autonomous mechanisms could also explain why EGFR kinase inhibitor 
fails in vivo and why aPKC inhibition is effective. For example, the tumor 
microenvironment plays a substantial role in influencing tumor progression (27–31). CD68+ 
macrophage or microglia cell infiltration was greater in the tumor area in glioblastoma tissue 
than in normal brain tissue in 37 of the 44 (~84%) cases examined (Fig. 3A). Mice with 
GBM6 cell–derived glioblastomas also showed increased staining for Iba1+ macrophage or 
microglia cells in the tumor (fig. S4A) compared to contralateral control regions (fig. S4B). 
Both classically activated (M1) macrophages and alternatively activated (M2) macrophages 
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have been identified in the tumor microenvironment (32). Fluorescence-activated cell 
sorting (FACS) analysis of glioblastomainfiltrating macrophages or microglia in three 
independent glioblastoma cases showed that although the predominant population was of the 
M2 macrophage subtype (CD23+), a smaller population was of the M1 subtype (CD64+) 
(Fig. 3B). Proinflammatory cytokines such as tumor necrosis factor–α (TNFα) are produced 
by tumor-associated myeloid cells and promote tumor initiation and progression (33, 34). 
When activated, in vitro differentiated M1 and M2 macrophages secreted TNFα (fig. S4C), 
and TNFα was detectable in all glioblastoma tissues examined, but not in normal brain (44 
cases) (Fig. 3C).
Activation of the nuclear factor κB (NF-κB) pathway is a strong oncogenic signal in many 
tumors, including glioblastoma (35–42). The deletion of NFKBIA, which encodes the NF-
κB inhibitor IκBα, occurs in about 20% of glioblastoma cases (43), and the activation of 
NF-κB, similar to EGFR gain of function, predicts poor prognosis in glioblastoma (43). 
However, the loss of IκBα overlaps with EGFR amplification in only 5% of glioblastoma 
cases, suggesting that these two independent tumor-intrinsic mutations do not occur 
simultaneously (43). Inflammatory signals in the tumor microenvironment such as TNFα 
commonly drives NF-κB activation in cancers such as colon cancer (36, 44, 45). Therefore, 
we tested whether NF-κB signaling was more active in glioblastomas with EGFR gain of 
mutation but without IκBα loss of function. Comparison of NFKBIA expression in two 
EGFR+ glioblastoma specimens revealed that NFKBIA expression was not reduced in 
comparison to normal human astrocytes. Furthermore, sequencing the exons identified that 
the loci contained synonymous substitutions, but no nonsynonymous mutations were 
detected in these samples (fig. S5). Quantitative RT-PCR (RT-qPCR) indicated that NF-κB 
target gene expression was higher in glioblastoma tumors than in normal human astrocytes 
(Fig. 3D). We also analyzed NOD/SCID mice bearing tumors derived from GBM6 cells and 
found that NF-κB–dependent gene activation was higher in the tumor side of the brain than 
in the contralateral, non–tumor-bearing side (Fig. 3E). Similarly, C57BL6 mice with tumors 
derived from GL261 mouse glioma cells showed increased NF-κB target gene expression in 
comparison to contralateral, non–tumor-bearing brain (fig. S4D). To validate the function of 
microenvironment-derived TNFα in glioblastoma tumor progression in vivo, we 
stereotactically injected C57BL6-derived GL261 mouse glioma cells into the caudate 
nucleus of either wild-type mice or mice lacking the TNFα gene (TNFα−/−). Mice with 
genetic ablation of TNFα survived significantly longer (median survival of 23 days) 
compared to wild-type mice (median survival of 16.5 days) (Fig. 3F). As anticipated, NF-κB 
target gene expression in tumor cells was significantly reduced in TNFα−/− mice (Fig. 3G). 
These results demonstrate that NF-κB signaling is active in glioblastoma, and suggest that it 
is likely driven by paracrine TNFα. This TNFα–NF-κB axis promotes glioblastoma 
progression and acts as an EGFR-independent oncogenic signal.
To test the role of myeloid cells and myeloid cell–derived factors, such as TNFα, on 
glioblastoma proliferation and invasion, we cocultured myeloid cells with GBM6 cells in 
vitro. Primary human monocytes or in vitro differentiated, but not undifferentiated, 
monocytic THP1 cells (46) that had been cocultured with GBM6 cells produced TNFα (Fig. 
4A and fig. S6, A to D). 5-Ethynyl-2′-deoxyuridine (EdU) incorporation assays indicated 
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that the proliferation of GBM6 cells increased when they were cocultured with monocytes, 
an increase that was reduced by the inclusion of an anti-human TNFα antibody in the culture 
medium (Fig. 4B and fig. S6E).
Rapid invasion of glioblastoma cells into the surrounding parenchyma is a defining 
characteristic of this disease and is believed to contribute to the failure of surgery and 
directed radiotherapy. Therefore, we tested the ability of green fluorescent protein (GFP)–
expressing GBM6 cells to invade rat brain slices (47) after they had been cultured in the 
absence or presence of primary human monocytes (fig. S7). GBM6 cells retained the ability 
to invade into the brain parenchyma when implanted onto rat brain slices ex vivo. The 
invasion of GBM6 cells was significantly enhanced when the cells were cocultured with 
monocytes, and the anti-human TNFα antibody blocked this enhanced invasion (Fig. 4C). 
Similarly, coculture of GBM6 cells with differentiated THP1 cells increased GBM6 cell 
proliferation and invasion, effects that were inhibited by anti-human TNFα antibody (fig. 
S8, A and B). The effect of myeloid cells on glioblastoma proliferation and invasion was 
independent of the PTEN status of the glioblastoma cells because coculture of differentiated 
THP1 cells also increased the proliferation and invasion of PTEN-deficient U87/EGFRvIII 
cells (fig. S8, C and D). Similarly, in an independent model of glioblastoma–myeloid cell 
interaction, coculture of GL261 mouse glioma cells derived from B6 mice with mouse bone 
marrow–derived macrophages resulted in the production of TNFα by mouse primary 
macrophages (fig. S9A) and increased tumor cell proliferation (fig. S9B) and invasion (fig. 
S9C). Our results are consistent with the facilitation of inflammation in cancers such as 
breast and colon cancer by tumor-associated macrophages (32, 48–50).
Paracrine TNFα induces aPKC activation and EGFR kinase inhibitor resistance in 
glioblastoma
Because aPKC promotes TNFα–NF-κB signaling (51–53), we hypothesized that aPKC 
activates TNFα-driven NF-κB activation in glioblastoma, and therefore, targeting aPKC 
would inhibit both the RTK and NF-κB pathways. We first determined that aPKC 
phosphorylation status indeed correlated with monocyte-stimulated glioblastoma 
proliferation and invasion. aPKC phosphorylation was enhanced in GBM6 cells by coculture 
with monocytes, an effect that was reduced when TNFα was neutralized (Fig. 4D).
Next, we examined whether paracrine TNFα could reduce the efficacy of EGFR kinase 
inhibitors in glioblastoma. Proliferation and invasion of GBM6 cells was significantly 
inhibited by the EGFR inhibitor erlotinib in vitro, effects that were negated by the addition 
of TNFα (Fig. 4, E and F). Erlotinib reduced both aPKC and EGFR phosphorylation in 
GBM6 cells, but the addition of TNFα correlated with enhanced phosphorylation of aPKC 
but not of EGFR (Fig. 4, G and H). Thus, myeloid cells increase glioblastoma cell 
proliferation and invasion and contribute to the reduced efficacy of EGFR kinase inhibitors 
through the production of TNFα in the tumor microenvironment and the stimulation of 
aPKC activity in glioblastoma cells.
Next, we directly tested whether aPKC activity was increased in GBM6 cells in response to 
TNFα. The phosphorylation of both aPKC and the p65 subunit of NF-κB (NF-κB p65) was 
significantly increased in GBM6 cells after the addition of TNFα (Fig. 5, A and B). 
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Additionally, PZ09 treatment of GBM6 cells resulted in significantly reduced expression of 
TNFα-induced NF-κB targets (Fig. 5C). FACS analysis indicated that PZ09 treatment 
inhibited the TNFα-dependent increase in the phosphorylation of Ser536 in NF-κB p65 in 
GBM6 cells (Fig. 5D). Similarly, aPKC (figs. S10A and S11A) and NF-κB p65 (fig. S11A) 
were activated upon TNFα stimulation in U251 glioma cells. Silencing aPKC in U251 cells 
with siRNA sequences targeting both PRKCI and PRKCZ decreased the expression of 
TNFα-induced NF-κB target genes (fig. S10B). Silencing aPKC in U251 cells prevented the 
TNFα-dependent phosphorylation of Ser311 in NF-κB p65 (fig. S10C) but only partially 
prevented the TNFα-induced degradation of IκBα (fig. S10D). Finally, PZ09 treatment or 
aPKC siRNA transfection of U251 cells reduced the TNFα-stimulated activity of a NF-
κB:GFP reporter to values comparable to those obtained with neutralization of TNFα with 
an anti-human TNFα antibody (fig. S10E).
We also tested the effects of inhibiting aPKC under GBM6–myeloid cell coculture 
conditions. Coculture of GBM6 cells and monocytes resulted in the enhanced 
phosphorylation of both aPKC and NF-κB p65 in GBM6 cells (fig. S11B). To assay 
monocyte-induced NF-κB target gene expression in GBM6 cells, we performed RT-qPCR 
on GBM6 cells exposed to the media of cocultured GBM6 cells and monocytes through a 
transwell system. In comparison to GBM6 cells grown in monoculture, GBM6 cells exposed 
to the coculture media showed increased expression of NF-κB target genes, such as COX2, 
IL1β, IL8, MCP1, MMP9, and TNFα (Fig. 5E). Similarly, in GBM6 cells cocultured with 
differentiated THP1 cells (46), aPKC phosphorylation peaked in GBM6 cells about 1 hour 
after plating (fig. S12A). NF-κB target gene expression in GBM6 (fig. S12B) or U87/
EGFRvIII cells (fig. S12C) was enhanced under coculture conditions with differentiated 
THP1 cells. Treatment with PZ09 reduced the induction of NF-κB target genes in GBM6 
cells exposed to GBM6 cell monocyte coculture media (Fig. 5E). These results demonstrate 
that tumor-associated myeloid cells activated aPKC-dependent NF-κB signaling.
Consistent with our hypothesis that aPKC-dependent NF-κB signaling induced by myeloid 
cells contributes to glioblastoma cell proliferation, PZ09 was also effective in inhibiting the 
monocyte-induced increase in GBM6 cell proliferation (Fig. 5F) and invasion (Fig. 5G), 
which correlated with inhibition of aPKC and NF-κB p65 phosphorylation (Fig. 5, H and I). 
Similarly, PZ09 treatment of cocultured GBM6 and differentiated THP1 cells reduced tumor 
cell proliferation (fig. S13A) and invasion (fig. S13B). aPKC knockdown in U87/EGFRvIII 
cells cocultured with THP1 cells resulted in reduced proliferation (fig. S13C) and invasion 
(fig. S13D). Because U87/EGFRvIII cells are deficient in PTEN, these results indicate that 
aPKC functions downstream of PTEN. PZ09 treatment or aPKC siRNA effectively inhibited 
the phosphorylation or reduced the abundance of aPKC, respectively, without affecting the 
total abundance or phosphorylation of EGFR in GBM6 or U251/EGFR cells (figs. S2, D and 
E, and S14, A to D). We also compared the efficacy of in vivo inhibition with erlotinib 
compared with PZ09 in a model of glioblastoma with the EGFRvIII mutation. In mice 
bearing orthotopic xenografts derived from U87/EGFRvIII cells, both erlotinib and PZ09 
were effective in decreasing EGFR signaling in the xenografts (as assessed by the 
abundance of CD44 and uPAR in tumors), but only PZ09 treatment significantly inhibited 
the expression of NF-κB target genes in xenografts (IL1β and TNFα) (Fig. 5J).
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Distinct aPKC-containing signaling complexes mediate oncogenic TNFα and RTK 
signaling
Do glioblastoma cell–autonomous EGFR and paracrine TNFα signals converge on an 
aPKC-containing signal module in glioblastoma cells? Whereas both EGF and TNFα 
signaling in glioblastoma resulted in aPKC activation and required aPKC, these pathways 
resulted in largely distinct transcriptional outputs at early time points. For example, EGF 
induced CD44, MMP9, VCAM, and uPAR (fig. S15A), whereas TNFα induced the 
expression of a different set of genes including IL1β, IL8, MCP1, and TNFα in U251/EGFR 
cells (fig. S15B). Furthermore, treatment with the extracellular signal–regulated kinase 
(ERK) inhibitor U0126 suggested that mitogen-activated protein kinase (MAPK) signaling 
downstream of aPKC promoted EGF-specific gene expression and not TNFα-dependent 
gene expression (fig. S15, C and D). In contrast, IκBαM, a dominant-negative inhibitor of 
NF-κB signaling, inhibited only TNFα-dependent gene expression, and not EGF-dependent 
gene expression, except for MMP9, indicating that aPKC-dependent NF-κB signaling was 
specifically required for the expression of the TNFα-dependent genes (fig. S15, E and F). 
These results suggest that although aPKC participates in both signaling pathways, these 
pathways do not merely converge on aPKC.
Two PB1 domain–containing scaffolds, Par6 and p62, can direct aPKC signaling to specific 
subsets of upstream activators and/or downstream substrates, thereby determining the 
functional specificity of aPKC activity (54). We investigated the requirement of the PB1 
domain–containing scaffolds necessary for aPKC activation in the context of TNFα and 
EGF signaling in glioblastoma cells. EGF induced or stabilized an aPKC-Par6 complex (Fig. 
6A). Application of EGFR kinase, PI3K, or Src inhibitors, all of which suppressed the 
activity of their targets (fig. S16), reduced aPKC activation and also reduced aPKC-Par6 
coimmunoprecipitation in U87/EGFRvIII cells (Fig. 6B). For EGF-induced genes, the effect 
of aPKC silencing was generally phenocopied by Par6 silencing (fig. S2, C and D), but not 
by p62 silencing (fig. S2D and Fig. 6C). In contrast, silencing p62 generally phenocopied 
aPKC silencing in inhibiting NF-κB signaling (Fig. 6D). Furthermore, immunofluorescence 
imaging demonstrated that the majority of cellular Par6 localized with actin at the leading 
edge of EGF-treated U251/EGFR cells, whereas p62 localized to an intracellular 
compartment in TNFα-treated U251/EGFR cells (Fig. 6E). Therefore, TNFα and EGF 
signaling pathways, despite sharing the downstream kinase aPKC, may use alternative PB1 
domain scaffold proteins—p62 or Par6—that localize to distinct intracellular regions. 
Expression of the constitutively active myr-aPKCζ in U251 cells resulted in indiscriminate 
induction of CD44, MMP9, VCAM, uPAR, IL1β, IL8, MCP1, and TNFα expression (Fig. 
6F). Together, our results suggest that activation of aPKC is not only indispensable but also 
sufficient for the induction of both EGF- and TNFα-dependent genes, and that the 
specificity of these pathways is determined by the differential use of adaptors Par6 and p62.
In conclusion, aPKC functions in parallel oncogenic signals in glioblastoma (Fig. 7). Altered 
abundance of this kinase has been previously reported to be associated with cancers, 
including glioblastoma (55). Two genes code for aPKCs in the mammalian genome. PRKCZ 
encodes aPKCζ, whereas PRKCI codes for aPKCΙ. The identity of the aPKCs involved in 
glioblastoma as well as their distribution pattern has heretofore remained unclear with 
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frequently contrasting reports. For example, aPKCζ has been reported to be both increased 
and decreased in abundance in cancer, including glioblastoma (55, 56). aPKCΙ, and not 
aPKCζ, is the aPKC detected in most brain regions, except for cerebellum (57). Our 
analyses revealed that most glioblastoma tumor cell lines, as well as patient-derived 
xenografts, express more PRKCI than PRKCZ (fig. S17, A to C). aPKCΙ protein but not 
mRNA abundance was increased in glioblastoma cell lines and patient-derived xenografts in 
comparison to normal human astrocytes (fig. S17, D and E), suggesting that aPKC protein 
amount in glioblastoma was increased through posttranslational mechanisms.
DISCUSSION
The success of single-agent antitumor therapy can be limited by downstream mutations or 
the induction of parallel oncogenic pathways in tumor cells. EGFR gain of function occurs 
in ~45% of glioblastoma cases; the homozygous deletion of PTEN leading to downstream 
PI3K activation is seen in ~36% cases; and overall PI3K activation (due to activation of 
other RTK pathways) is seen in ~88% of glioblastoma cases (58). Cancer cells with mutant 
EGFR are particularly sensitive to inhibition of NF-κB, and NF-κB activation through 
overexpression of c-FLIP or silencing of IκBα rescues EGFR-mutant cancer cells from the 
cytotoxic effects of erlotinib (59). Our results indicate that a proinflammatory 
microenvironment provides parallel oncogenic signals that increase the therapeutic 
challenge of targeting glioblastoma tumor–intrinsic mutations (Fig. 7). Infiltration of innate 
immune cells within the glioblastoma tumor mass has been described previously (60–64). 
However, glioblastoma is not traditionally considered an inflammation-driven tumor, and 
macrophages or activated microglia in glioblastoma have often been described as 
antitumorigenic (65, 66). Here, we demonstrate that the interaction of glioblastoma tumor 
cells with tumor-infiltrating myeloid cells leads to paracrine production of TNFα, which 
contributes to tumor growth and spread and renders EGFR kinase inhibitors less effective. 
These results are consistent with previous reports that macrophages and microglia enhance 
glioma invasion and growth. Microglia, but not oligodendroglia or endothelial cells, can 
increase GL261 glioma cell migration in vitro (67, 68). Depletion of macrophages and 
microglia by treatment with clodronate liposomes also reduces invasion of GL261 cells in 
organotypic brain slices (69), and in vivo deletion of macrophages or microglia in the brain 
or the inhibition of colony-stimulating factor 1 (CSF-1) receptor reduces glioma growth 
(70–72). Additionally, high-grade gliomas, such as glioblastoma and WHO grade III 
anaplastic astrocytomas, show the largest increase in macrophage infiltration, in contrast to 
low-grade gliomas (62). Radioresistance in glioblastoma and a conversion to a more 
aggressive, mesenchymal subtype have been ascribed to TNFα/NF-κB signaling (73). Thus, 
targeting the tumor microenvironment can provide therapeutic opportunities (74, 75).
In summary, aPKC has critical roles in distinct but concurrent oncogenic signaling 
pathways. It functions downstream of EGFR and RTK signaling in glioblastoma cells. It is 
also essential for tumor microenvironment–induced TNFα–NF-κB oncogenic signaling in 
glioblastoma. Targeting the activity of aPKC in tumor cell–autonomous and non–tumor 
cell–autonomous signaling may be a strategy that affords simultaneous disabling of tumor-
intrinsic as well as microenvironment-induced oncogenic signals in glioblastoma.
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Six- to 8-week-old female NOD-SCID mice were acquired from Charles River. TNFα−/− 
(B6.129S6-Tnftm1Gkl/J, stock 5540) and control C57BL/6J (stock 664) were acquired from 
The Jackson Laboratory. All animal procedures conformed to protocols approved by the 
University of Arizona Institutional Animal Care and Use Committee (IACUC).
Antibodies and reagents
Rabbit anti-aPKC (sc-216) and rabbit anti–NF-κB p65 phosphoSer311 (sc-101748) were 
purchased from Santa Cruz Biotechnology. Rabbit anti–aPKC phosphoThr410/403 (#9378), 
rabbit anti–NF-κB p65 phosphoSer536 (#3033), rabbit anti–Akt phosphoSer473 (#9271), 
mouse anti-Akt (#2920), rabbit anti–Src phosphoTyr516 (#6943), rabbit anti-Src (#2123), 
rabbit anti–MAPK p44/42 (#4695), rabbit anti–NF-κB p65 (#4764), and rabbit anti-IκBα 
(#9242) were obtained from Cell Signaling. Rabbit anti-PAR6 (ab49776), rabbit anti–aPKC 
phosphoThr560 (ab62372), rabbit anti–aPKC phosphoT560 (ab62372), and mouse anti-p62 
(ab56416) were purchased from Abcam. Rabbit anti–EGFR phosphoTyr1086 (44790) and 
mouse anti-EGFR (44796) were purchased from Invitrogen. Mouse anti–EGFR 
phosphoTyr1086 (04-286) was purchased from Millipore. Mouse anti–β-tubulin (T-2046) and 
mouse anti–MAPK p44/42 phosphoThr183-phosphoTyr185 (M-8159) were purchased from 
Sigma. Mouse anti-human CD68 antibody (#M0814) was purchased from Dako. Mouse 
anti-human TNFα neutralizing antibodies from Novus Biologicals (#NB120-10204) or from 
R&D Systems (MAB2101) were used at a concentration of 100 ng/ml. Mouse 
immunoglobulin G1 (IgG1) isotype controls (MAB002 or NBP1-97005) were purchased 
from Novus Biologicals and R&D Systems and used at identical concentrations as the TNFα 
neutralizing antibodies. Rat anti-mouse Cd11b–phycoerythrin (PE) (#12-0112-85), mouse 
anti-human TNFα-allophycocyanin (APC) (#17-7349-82), and mouse IgG1 isotype control 
(#17-4714-81) antibodies were acquired from eBioscience. PE–mouse anti-human TNFα 
(#502908), PE–mouse IgG1k isotype control (#400139), anti-human CD11b–Pacific blue 
(#101235), anti-human CD64–Alexa Fluor 647 (#305012), anti-human CD23–APC–cyanine 
7 (Cy7) (#338520), anti-human CD14-PECy7 (#325617), anti-human CD80–fluorescein 
isothiocyanate (#305205), and anti-human CD163 (#333608) antibodies used for FACS 
were obtained from BioLegend. Species-specific secondary antibodies for 
immunohistochemistry or immunofluorescence conjugated to Alexa 488 or 594 were 
obtained from Life Technologies. Secondary antibodies for Western [anti-mouse–
horseradish peroxidase (HRP) and anti-rabbit–HRP] were obtained from Promega. Erlotinib 
was purchased from Selleck Chemicals (S1023) and was used at a concentration of 10 μM. 
All other inhibitors were purchased from Calbiochem. AG1478 (#658548) was used at 10 
μM; PI3K inhibitors LY294002 (#44024) and wortmannin (#681675) at 20 μM and 100 nM, 
respectively; MAPK kinase inhibitor U0126 (#662005) at 10 μM; and Src kinase inhibitor 
SU6656 (#572636) at 10 μM. NF-κB-Reporter:GFP lentivirus was obtained from SA 
Biosciences (CLS-013G). The IκBαM adenovirus was purchased from Imgenex 
(IMG-2500). Lentiviruses expressing GFP or aPKC shRNA constructs were produced at 
Viral Vector Core, The Salk Institute, according to previously described methods (76). 
VSVg (vesicular stomatitis virus G glycoprotein) pseudotyped constitutively active IκB 
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kinase (IKK) (S177,181E) retrovirus was generated as previously described (77) with minor 
modifications. pCLXSN-IKK S177,181E was transiently transfected into human embryonic 
kidney (HEK) 293T cells using linear 25-kD polyethylenimine (Polysciences Inc.) with an 
N/P ratio (ratio of moles of amine groups of cationic polymers to phosphates of DNA) of 10 
[1 mg/ml in Dulbecco-PBS (phosphate-buffered saline), pH 4.5]. Cells were cotransfected 
with pCL-CMV-GAG-POL and pMD2.G. Virus-containing medium was harvested at 48 
and 72 hours after transfection, treated with deoxyribonuclease 1 (1 μg/ml; Sigma), and 
filtered through a 0.22-μm filter (Durapore, Millipore) before aliquoting and storage at 
−80°C. Infectious viral titers were determined by RT-qPCR of genomic DNA extracted 
from HEK293T cells 48 hours after infection with a 10-fold dilution series of retroviral 
vector. PZ09 was synthesized in-house following a previously described procedure (13) with 
some modifications, and the inhibitor was validated by mass spectrometry and in vitro 
kinase assays. PZ09 was used at 10 μM.
Cell lines and cell culture
U87/EGFRvIII and U251/EGFR human glioblastoma cell lines were a gift from Z. Lu (MD 
Anderson). The murine GL261 glioma cell line was acquired from the National Cancer 
Institute. The primary glioblastoma line 6 (GBM6) cell line was established directly from a 
patient surgical sample and maintained as a subcutaneous flank xenograft through serial 
passaging in immunodeficient mice. GBM6 flank tumor xenografts were harvested, 
mechanically disaggregated, and grown in short-term culture (5 to 7 days) in Dulbecco’s 
modified Eagle’s medium (DMEM) containing 2.5% fetal bovine serum (FBS), 1% 
nonessential amino acids, 2 mM glutamine, penicillin (100 U/ml), and streptomycin (10 
μg/ml) for lentiviral transduction (15). Primary glioma cells were dissociated from fresh 
patient tumors using the Miltenyi Biotec Brain Tumor Dissociation Kit (#130-095-939) and 
the Miltenyi gentleMACS dissociator. Glioma cells were isolated according to a previously 
published protocol (78). Samples were taken from patients diagnosed with glioblastoma, and 
the use of the patient tissues received prior Barrow Neurological Institute/St. Joseph’s 
Hospital Institutional Review Board authorization. Unless indicated otherwise, all cell types 
were grown in DMEM supplemented with 10% FBS and 1% penicillin/streptomycin (p/s) 
(Invitrogen) at 37°C, 5% CO2. THP1 cells were maintained in DMEM supplemented with 
10% FBS, 1% p/s, and 0.05 mM 2-mercaptoethanol. THP1 cells were differentiated with 
phorbol 12-myristate 13-acetate (PMA; 50 ng/ml) (Cell Signaling) overnight and were 
subsequently washed three times with PBS. Medium was then replaced, and the cells were 
cultured for an additional 24 hours before experiments. siRNA and shRNA were transfected 
using Lipofectamine (Life Technologies) or Effectene (Qiagen), respectively. siRNAs were 
purchased from Life Technologies. Transfection was performed according to established 
protocols from the manufacturers. Cells were analyzed 48 hours after transfection. Average 
knockdown efficiency for PRKCZ, PRKCI, PAR6A, PAR6B, and P62 relative to control 
(luciferase) siRNA is shown in fig. S1. U87/EGFRvIII cells were transduced with lentiviral 
vector alone or with lentivirus aPKC-shRNA to generate stable lines (U87VIII control cells 
and U87VIII-aPKC-shRNA cells). Glioblastoma cells were incubated with 1:5000 dilution 
of virus in serum-free medium overnight. Subsequently, the cells were washed three times 
with PBS and cultured according to standard protocols. The cells were cultured for an 
additional 48 hours after infection before conducting experiments. For EGF and TNFα 
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treatments, cells were serum-starved for 24 hours and then treated with EGF (100 ng/ml; 
Millipore) or TNFα (10 ng/ml; Calbiochem) for various time points. PZ09 was used at 10 
μM. For other inhibitors, cells were serum-starved overnight and preincubated with inhibitor 
for 30 min.
Immunoblotting and immunoprecipitation
Ice-cold 1% NP-40 buffer (20 mM tris-HCl at pH 8, 137 mM NaCl, 10% glycerol, 1% 
NP-40) supplemented with phosphatase and protease inhibitor (Halt Protease and 
Phosphatase Inhibitor Cocktail, Thermo Scientific) was used for protein isolation and 
immunoprecipitation. Briefly, cells were washed three times with ice-cold PBS and scraped 
in NP-40 buffer. Lysates were kept cold and sonicated 10 times, 1 s each, and then 
centrifuged at 12,000g for 5 min at 4°C. For immunoprecipitation, the supernatant was 
precleared using protein-A beads for 30 min at room temperature (RT). The supernatant was 
subsequently added to protein-A beads prebound to aPKC antibody (Santa Cruz 
Biotechnology, sc-216), and the mixture was incubated overnight on a shaker at 4°C. 
Immunoprecipitates were then washed two times with ice-cold NP-40 buffer and finally 
washed with PBS. Sample loading buffer with dithiothreitol was added, and the 
immunoprecipitates were boiled for 5 min before loading onto precast SDS–polyacrylamide 
gel electrophoresis gels (Life Technologies). Gels were transferred onto methanol-presoaked 
polyvinylidene difluoride membranes and subsequently blocked with 5% bovine serum 
albumin (BSA) in PBS for 2 hours. Primary antibodies were incubated overnight at 4°C, 
after which blots were washed three times with TBST [tris-buffered saline (TBS) + 0.1% 
Tween] for 15 min each, followed by incubation with secondary antibodies (1: 2000) for 2 
hours at RT. Blots were then washed three times for 30 min each in TBST, with a final wash 
in TBS alone. Blots were developed using SuperSignal West Dura (Thermo Scientific) on a 
UVP Imager.
Immunohistochemistry for tissue microarrays
Tissue microarrays were prepared from archival blocks of formalin-fixed paraffin-embedded 
specimens of WHO grade IV glioblastoma. All tumor cases were histologically reviewed, 
and representative tumor areas were marked on the corresponding donor paraffin blocks. 
Blocks were cut at 4-μm thickness for routine hematoxylin and eosin (H&E) staining and 
immunohistochemistry. Sources for tissue microarrays include TGen, Armed Forces 
Institute of Pathology, and Barrow Neurological Institute. Immunohistochemistry was 
performed using Ventana automated Discovery XT or Benchmark XT system (VMSI, 
Ventana Medical Systems, a member of the Roche Group). All steps were performed on this 
instrument using VMSI validated reagents, including deparaffinization, cell conditioning 
(mild CC1 for CD68 and standard CC1 for aPKC, phospho-aPKC, and TNFα), primary 
antibody staining, detection, and amplification using a biotinylated streptavidin-HRP and 
ultraVIEW Universal DAB (diaminobenzidine) detection system and hematoxylin 
counterstaining. Primary antibodies were incubated for 30 min (CD68 and TNFα) or 1 hour 
(aPKC and phospho-aPKC) at 37°C. Appropriate positive and negative (secondary antibody 
only) controls were stained in parallel for each round of immunohistochemistry. After 
staining on the instrument, slides were dehydrated through graded alcohols to xylene and 
coverslipped with mounting medium.
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Six- to 8-week-old female NOD-SCID, TNFα−/−, and control mice were anesthetized by 
intraperitoneal injection of 1.25% avertin (200 mg/kg). Cells (U87EGFRvIII control, U87/
EGFRvIII-aPKC-shRNA, or GL261) were resuspended in standard medium (DMEM with 
10% FBS, 1% p/s) at a concentration of 1.25 × 105 cells/μl and kept on ice until injection. 
Intracranial injections were performed using a Hamilton syringe (Hamilton Company). 
Briefly, the animal was secured onto the small animal stereotaxic apparatus (Kopf 
Instruments), and a midline incision was made to expose the skull. Subsequently, a burr hole 
was drilled 1 mm lateral and 2 mm anterior to bregma. Cells were injected at a rate of 1 
μl/min (total 4 μl, 5 × 105 cells) to a depth of 3 mm below the skull, which corresponds to 
the area of the caudate nucleus. For GBM6 cell intracranial tumor model, 2 × 106 GBM6 
cells were injected. For PZ09 treatment, 10 μM PZ09 was delivered by ALZET minipumps 
directly to the tumor site, 3 days after implantation, for a treatment period of 7 days in mice 
bearing U87/EGFRvIII cell–derived tumors and for 14 days in mice bearing GBM6 cell–
derived tumors. After intracranial injection, mice were observed daily for changes in weight, 
gait, and appearance and neurological symptoms and were euthanized according to IACUC 
recommendations. Brains were then removed and processed for histopathology.
RNA isolation and RT-PCR
For gene expression analysis from short-term cultures of GBM6 and other glioblastoma cell 
lines, total cellular RNA was isolated with RNeasy kit (Qiagen). mRNA was reverse-
transcribed into complementary DNA (cDNA) using the Superscript III Kit (Life 
Technologies). Real-time PCR was performed on a 7900HT cycler with SYBR Green 
Master Mix (Applied Biosystems). For NF-κB target gene profiling from primary human 
glioblastoma cells, cDNA was obtained as described and plated onto a Custom TaqMan 96-
well Gene Expression Signature Plate according to the manufacturer’s instructions. Real-
time PCR was performed on a 7900HT cycler with TaqMan Universal PCR Master Mix 
(Life Technologies). For acutely isolated in vivo mouse brain mRNA analyses, whole mouse 
brain was homogenized in Trizol using a glass homogenizer. Samples were centrifuged, and 
0.2 ml of chloroform per 1 ml of Trizol was added to the supernatant. Samples were 
vigorously shaken for 15 s, incubated at RT for 3 min, and centrifuged for 15 min at 10,000g 
at 4°C. Addition of chloroform and centrifugation was repeated. After second centrifugation, 
the aqueous phase containing RNAwas precipitated by mixing with isopropyl alcohol for 20 
min at −20°C. RNA precipitants were washed three times with 75% ethanol and spun at 
7500g for 5 min at 4°C. RNA was air-dried, resuspended in ribonuclease-free water, and 
stored at −80°C. For wild-type EGFR and EGFRvIII, cDNA was amplified by standard PCR 
using primers as previously described (7) and resolved on agarose gel. Primers were 
purchased from IDT, and sequences are provided in table S1.
Human monocyte isolation and monocyte-derived macrophages
Peripheral blood mononuclear cells (PBMCs) were obtained from 50 ml of buffy coats (New 
York Blood Center) by Ficoll gradient centrifugation. Human monocytes were isolated by 
CD14-positive selection (STEM-CELL) from PBMCs. CD14+ monocytes were cocultured 
with GBM6 cells at 1:1 ratio for in vitro proliferation or invasion assays. CD14+ monocytes 
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(300,000 to 500,000/ml) were plated in RPMI 1640 plus 10% of FBS and in vitro 
differentiated to macrophages by adding macrophage-CSF (25 ng/ml). Interferon-γ (50 ng/
ml), IL-4 (40 ng/ml), or IL-10 (50 ng/ml) polarizing cytokines were added on day 3, and 
M0, M1, M2a, and M2c monocyte-derived macrophages were harvested on day 7. 
Macrophage polarized phenotype was confirmed using anti-human CD11b, CD64, CD23, 
CD80, CD163, and CD14 (BioLegend). Recombinant cytokines were purchased from R&D 
Systems.
Coculture and ELISA
For transwell coculture experiments, 1 × 106 glioma cells were plated into a six-well plate. 
Cell culture inserts (Millicell, 0.4-μm micropore polycarbonate filter) were placed in the 
wells. GBM6 or U87/EGFRvIII cells were serum-starved for 24 hours before adding 1 × 105 
glioblastoma cells alone, glioblastoma plus 1 × 105 THP1 cells, or glioblastoma cells plus 
primary monocytes (CD14+) to the insert. At specified time points, cell culture inserts were 
removed, and RNA was isolated from the glioblastoma cells alone. In addition, medium 
supernatants were collected, snap-frozen with liquid nitrogen, and stored at −80°C. The 
media from cocultures of macrophages and tumor cell lines were collected after 24 and 48 
hours, and TNFα in the supernatants was detected using an anti-TNFα ELISA kit 
(eBioscience). For proliferation assays, starved 1 × 105 glioblastoma cells were cocultured 
with 1 × 105 CD14+ monocytes or differentiated THP1 cells in a six-well plate, and EdU 
incorporation was assessed following the manufacturer’s instructions (Click-iT EdU Flow 
Cytometry Assay Kit, Life Technologies). CD11b staining was included to identify 
monocytes and distinguish them from glioblastoma cells in coculture.
Flow cytometric analysis
Glioma cell lines, undifferentiated or PMA-differentiated THP1 cells, and CD14+ primary 
monocytes were cultured alone and together in complete DMEM at a 1:1 ratio. Six hours 
before harvesting, brefeldin A was added to cells at a final concentration of 3 μg/ml. CD11b 
surface staining was included to discriminate primary monocytes from glioma cells. Cells 
were fixed with 1% paraformaldehyde (PFA) and permeabilized with 0.5% saponin. Anti-
TNFα antibody or isotype control was added to cells, and cells were incubated on ice for at 
least 30 min. Cells were then washed with Dulbecco-PBS and suspended in 1% BSA 
solution. For NF-κB p65 phosphoSer536 (Cell Signaling Technology), EGFR 
phosphoTyr1086 (Millipore), and aPKC phosphoThr560 (Abcam) staining, GBM6 cells were 
treated with TNFα (100 ng/ml; Calbiochem) or serum or cocultured with monocytes for 
different times. After harvesting, cells were immediately fixed with 1% PFA for 15 min, 
washed two times with PBS, and then permeabilized with cold methanol for 30 min on ice. 
Cells were washed three times, blocked with PBS + 5% human AB serum for 15 min, and 
then incubated with specific antibodies for 30 min at 4°C. For non–fluorochrome-conjugated 
primary antibodies, anti-rabbit APC (BioLegend) and anti-mouse Alexa Fluor 488 
(eBioscience) were used as secondary antibodies. CD11b antibody was always added when 
GBM6 cells were cocultured with monocytes. Cells were finally washed and resuspended in 
PBS for FACS analysis. For bromodeoxyuridine (BrdU) incorporation experiments, 1 × 106 
U87/EGFRvIII or GBM6 cells were plated in a six-well plate. Cell culture inserts (Millicell, 
0.4-μm micropore polycarbonate filter) were placed in the wells. Glioma cells were serum-
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starved for 24 hours before adding 1 × 105 U87/EGFRvIII or GBM6 cells and 1 × 105 THP1 
to the insert. BrdU (10 μM; BD Pharmingen, 552598) was added to the media for 24 hours. 
Cell culture inserts were removed, and glioma cells were fixed, permeabilized, and stained 
for BrdU using an APC BrdU Flow Kit (BD Pharmingen, 552598) according to the 
manufacturer’s instructions. For EdU incorporation, starved 1 × 105 GBM6 cells were 
cocultured with 1 × 105 CD14+ monocytes isolated from PBMC in a six-well plate for 24 
hours. EdU was added into the culture at the last 2 hours. After harvesting, cells were 
immediately fixed with the fixative buffer, supplied with the kit (Click-iT EdU Flow 
Cytometry Assay Kit, Life Technologies). Staining was performed following the 
manufacturer’s instruction. CD11b staining was included to identify monocytes and 
distinguish them from glioblastoma cells in coculture. For in vivo phenotypic analyses of 
tumor-infiltrating macrophages within human glioblastoma tumors, three patient samples 
were dissociated using the Miltenyi Biotec Brain Tumor Dissociation Kit and gentleMACS 
dissociator. Dissociated cells were blocked using 3% FBS in PBS for 30 min on ice and 
subsequently stained with a cocktail of anti-human CD23, anti-human CD64, and anti-
human CD11b in 3% FBS/PBS for 30 min on ice. Cells were washed three times with PBS 
and fixed in 1% PFA for 30 min on ice. FACSCalibur, FACSAria, or LSRII (BD) was used 
to analyze the samples, and WinMiDi software (freeware from The Scripps institute) or 
FlowJo was used to analyze and plot the data.
Ex vivo invasion assay
Ex vivo orthotopic invasion assays were performed as previously described (47) with some 
modifications. Brains were obtained from 4-week-old rats and placed in ice-cold artificial 
CSF (aCSF) (126 mM NaCl, 3 mM KCl, 1.5 mM MgCl2, 24 mM CaCl2, 1.2 mM NaH2PO4, 
11 mM glucose, and 26 mM NaHCO3). Brains were sectioned into 400-μm slices on a 
vibratome in ice-cold aCSF. Slices were placed on a cell culture insert (Millicell, 0.4-μm 
micropore polycarbonate filter) in a six-well plate with 1.5 ml of DMEM with 10% FBS and 
1% p/s; 500 μl of medium was added to the insert that was placed inside the wells of a six-
well plate. The brain slices were kept in an incubator under standard culture conditions 
(37°C, 5% CO2). GFP+ GBM6 and/or U87/EGFRvIII cells were resuspended in serum-free 
DMEM at 2 × 108 cells/ml. Before cells were added, medium was removed from the upper 
chamber of the six-well plate so that the slice was semidry before implantation. GFP+ 
GBM6 and/or U87/EGFRvIII cells (1 × 105) were placed on the putamen in 0.5-μl volumes, 
and after 45 min, 500 μl of serum-free medium was added back to the upper chamber. The 
plates were kept in the incubator for 4 to 5 days and subsequently fixed overnight in 4% 
PFA at 4°C. The polycarbonate membrane was carefully removed, and the brains were 
placed on a slide for imaging on a confocal microscope. Imaging and quantification were 
performed as previously described (47). Fluorescence at various depths into the tissue was 
calculated after confocal imaging. Intensity at each layer was normalized to total intensity 
across all depths, and linear regression analysis was performed to determine the slope of 
invasion for each replicate. R2 (coefficient of determination) for each slope was calculated 
and was greater than 0.88 with an average value of 0.96. The average inverse slope was used 
to calculate the invasion index.
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U251/EGFR or U251/EGFR-aPKC-siRNA cells were incubated with 1:1000 dilution of 
Lenti NF-κB-Reporter:GFP in serum-free medium overnight. Subsequently, the cells were 
washed three times with PBS and cultured for 72 hours before overnight serum starvation. 
After serum starvation, cells were treated for 30 min with TNFα (10 ng/ml) in serum-free 
medium in the presence or absence of 10 μM PZ09 or monoclonal anti-human TNFα 
antibody. Changes in GFP fluorescence were detected and quantified using a Tecan Infinite 
F500 microplate reader. Results were normalized to NF-κB reporter–transduced cells, which 
were serum-starved and not treated with TNFα.
Immunofluorescence
Glioblastoma cells were seeded onto acid-etched coverslips (70% ethanol, 1% HCl in PBS, 
5 min) in a 24-well plate overnight. Upon confluency, medium was removed and the cells 
were washed three times with PBS. The cells were fixed with 4% PFA for 15 min at RT, 
then washed three times with PBS, and permeabilized with 0.1% Triton-X–PBS for 15 min 
at RT. Cells were blocked for 2 hours with 2% normal horse serum (Life Technologies) in 
PBS at RT. Primary antibodies were diluted in 2% normal horse serum, and cells were 
incubated overnight at 4°C. Subsequently, coverslips were washed three times with PBS, 
and secondary antibodies (Alexa Fluor 488 and 594) diluted in 2% normal horse serum were 
added for 2 hours at RT. After the secondary antibody incubation, cells were stained with 4′,
6-diamidino-2-phenylindole (diluted at 1:5000 in PBS) for 10 min at RT. Finally, coverslips 
were washed three times with PBS and mounted onto slides using ProLong Gold antifade 
reagent (Life Technologies) and sealed with nail polish. Images were obtained using a Zeiss 
710 confocal microscope with a 63× objective lens.
Statistical analysis
Data are represented as means ± SEM. Differences between the means of experimental 
groups were analyzed with either one-tailed or two-tailed Student’s t test or analysis of 
variance (ANOVA) (GraphPad Software Inc.) as appropriate. Bonferroni multiple 
comparison test was used following ANOVA. Survival was calculated using Kaplan-Meier 
plot, and survival curves were compared by the Mantel-Cox log-rank test (GraphPad 
Software Inc.). P values ≤0.05 were considered significant.
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Fig. 1. Clinical association and therapeutic efficacy of targeting aPKC in mouse models of 
glioblastoma
(A to C) Representative immunohistochemistry showing that nontumor brain parenchyma 
shows low-intensity aPKC staining (A), whereas glioblastoma shows increased aPKC 
staining (B and C). Scale bar, 500 μm. (D) Stratification of 330 glioblastoma cases 
according to the immunohistochemical scores for aPKC staining. (E) Representative 
examples of aPKC phosphoThr410/403 staining in the glioblastoma tissue microarray. Scale 
bar, 500 μm. (F) Stratification of 44 glioblastoma cases according to immunohistochemical 
scores of aPKC phosphoThr410/403 staining. (G) Kaplan-Meier survival curve of 44 
glioblastoma cases showing correlation of bright aPKC staining with poor survival in human 
patients (P = 0.0145). (H) Kaplan-Meier survival curves of mice bearing intracranial 
xenografts derived from U87/EGFRvIII cells stably transfected with control or aPKC 
shRNA (P = 0.0005). (I) Representative images (left) and tumor volume (right) of tumors 
derived from U87/EGFRvIII cells and U87/EGFRvIII cells with aPKC knockdown. Dashed 
lines circumscribe the tumor areas. Scale bar, 1 mm. (J and K) Tumor volume of 
intracranial xenografts derived from U87/EGFRvIII cells (J) or EGFR kinase inhibitor–
insensitive GBM6 cells (K) in mice infused with PZ09 for 7 and 14 days, respectively. Data 
from (A) to (K) are presented as representative individual samples or as means ± SEM of at 
least three independent samples per group. *P < 0.05, **P < 0.01.
Kusne et al. Page 22













Fig. 2. aPKC is activated downstream of tumor-intrinsic oncogenic RTK signaling pathways
(A) Activation of aPKC in GBM6 cells after EGF treatment for the indicated times. Active 
aPKC was detected after aPKC immunoprecipitation followed by aPKC phosphoThr410/403 
immunoblotting. The blot was stripped and reprobed with aPKC. Representative (left) and 
quantified data from all experiments (right) are presented. (B) Expression of the indicated 
genes in GBM6 cells upon treatment with EGF alone or in the presence of PZ09 or erlotinib, 
as detected by RT-qPCR and normalized to GBM6 control cells. (C) Activation of aPKC in 
U251/EGFR cells after EGF treatment for the indicated times. (D) Expression of the 
indicated genes in U251/EGFR cells, U251/EGFR cells treated with erlotinib, or U251/
EGFR cells transfected with aPKC siRNA and treated with EGF, as detected by RT-qPCR 
and normalized to U251/EGFR control cells. (E) Activation of aPKC in U251/EGFR cells 
after transfection with vector alone or active Ras (H-RasV12), active PI3K (CAAXp110), or 
active Src (v-Src). Data for (A) to (E) are presented as representative images or as means ± 
SEM of at least three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001.
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Fig. 3. Myeloid cells, TNFα, and NF-κB–dependent gene expression are detected in glioblastoma 
and favor progression
(A) Representative images showing increased CD68+ staining in glioblastoma tissue in 
comparison to nontumor brain. Thirty-seven of 44 glioblastomas examined showed more 
intense CD68+ staining. Scale bar, 500 μm. (B) Representative FACS analysis and 
percentage of CD11b+CD64+ and CD11b+CD23+ tumor-infiltrating myeloid cells in three 
human glioblastomas. (C) Representative images showing increased TNFα staining in 
glioblastoma tissue in comparison to nontumor brain (n = 44). Scale bar, 500 μm. (D) NF-
κB target gene profiling of primary human glioblastoma from two different patients and 
normal human astrocytes, as detected by RT-qPCR. Gene expression in glioblastoma cells 
was normalized to the gene expression in astrocytes. (E) Expression of NF-κB target genes 
in acutely isolated tissue from the side of NOD/SCID mouse brain bearing GBM6 cell–
derived tumors in comparison to the contralateral, non–tumor-bearing brain as detected by 
RT-qPCR. n = 3 mice. (F) Kaplan-Meier survival curves for wild-type (WT) and TNFα−/− 
mice bearing GL261 cell–derived intracranial xenografts (P = < 0.0001). (G) Expression of 
NF-κB target genes in acutely isolated GL261 cell–derived tumor tissue from TNFα−/− and 
WT mice. n = 3 mice per genotype. **P < 0.01; ***P < 0.001; ns, nonsignificant.
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Fig. 4. Myeloid cell–derived TNFα promotes glioblastoma proliferation and invasion and EGFR 
kinase inhibitor resistance and correlates with aPKC activation
(A) Concentration of TNFα in conditioned media from monocytes, GBM6 cells, or GBM6 
cells cocultured with monocytes, as detected by enzyme-linked immunosorbent assay 
(ELISA). (B) Representative FACS analysis (left) and percentage (%) of EdU incorporation 
(right) in GBM6 cells cultured alone or cocultured with monocytes in the presence of 
monoclonal anti-human TNFα antibody or an isotype control. (C) Invasion indices of 
GBM6 cells cocultured with monocytes in the presence of monoclonal anti-human TNFα 
antibody or isotype control. (D) Representative FACS histograms (left) and mean 
fluorescence intensity (MFI; right) of phosphorylation of Thr560 in aPKC in GBM6 cells 
cultured alone or cocultured with monocytes in the presence of monoclonal anti-human 
TNFα antibody or an isotype control antibody. (E) Representative FACS analysis (left) and 
percentage (%) of EdU incorporation (right) in GBM6 cells left untreated or treated with 
erlotinib ± TNFα. (F) Invasion indices of GBM6 cells left untreated or treated with erlotinib 
± TNFα. (G) Representative FACS histograms (left) and MFI (right) of phosphorylation of 
Tyr1086 in EGFR in GBM6 cells left untreated or treated with erlotinib ± TNFα. (H) 
Representative FACS histograms (left) and MFI (right) of phosphorylation of Thr560 in 
aPKC in GBM6 cells left untreated or treated with erlotinib ± TNFα. Data for (A) to (H) are 
presented as representative individual samples or as means ± SEM of at least three 
independent samples per group. *P < 0.05; **P < 0.01; ***P < 0.001; ns, nonsignificant.
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Fig. 5. TNFα-induced NF-κB signaling in glioblastoma depends on aPKC
(A) Representative FACS histograms (left) and MFI (right) of the phosphorylation of Thr560 
in aPKC at the indicated times in GBM6 cells left untreated or treated with TNFα. (B) 
Representative FACS histograms (left) and percentage (%, right) of the phosphorylation of 
Ser536 in NF-κB p65 at the indicated times in GBM6 cells left untreated or treated with 
TNFα. (C) Expression of NF-κB target genes in GBM6 cells upon treatment with TNFα 
alone or with PZ09, as detected by RT-qPCR. mRNA abundance was normalized to GBM6 
cell control. (D) Representative FACS histograms (left) and percentage (right) of the 
phosphorylation of Ser536 in NF-κB p65 in GBM6 cells left untreated or treated with TNFα 
and with or without PZ09. (E) Expression of NF-κB target genes in GBM6 cells exposed to 
monocyte coculture media, in the presence or absence of PZ09, as detected by RT-qPCR 
and normalized to untreated GBM6 cell samples alone. (F) Representative FACS analysis 
(left) and percentage (right) of EdU incorporation in GBM6 cells cultured alone or cells 
cocultured with monocytes, with or without PZ09. (G) Invasion indices of GBM6 cells 
cultured alone or after coculture with monocytes in the presence or absence of PZ09. (H) 
Representative FACS histograms (left) and MFI (right) of the phosphorylation of Thr560 in 
aPKC in GBM6 cells cultured alone or when cocultured with monocytes in the presence or 
absence of PZ09. (I) Representative FACS histograms (left) and percentage (right) of the 
phosphorylation of Ser536 NF-κB p65 in GBM6 cells cultured alone or when cocultured 
with monocytes in the presence or absence of PZ09. (J) Gene expression in acutely isolated 
U87/EGFRvIII cell–derived intracranial tumors after mice were treated with saline, 
erlotinib, or PZ09. Data for (A) to (J) are presented as representative images or as means ± 
SEM of at least three independent samples per group. *P < 0.05; **P < 0.01; ***P < 0.001; 
ns, nonsignificant.
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Fig. 6. aPKC functions in both EGF- and TNFα-induced signaling in glioblastoma cells
(A) Coimmunoprecipitation of Par6 with aPKC in serum-starved U251/EGFR cells after 
EGF treatment. aPKC immunoprecipitates were sequentially probed with Par6 and aPKC 
antibodies. Lysates were immunoblotted for Par6. (B) Coimmunoprecipitation of Par6 and 
activation of aPKC in U87/EGFRvIII cells grown in serum after incubation with AG1478, 
wortmannin, LY294002, or SU6656. aPKC immunoprecipitates were sequentially probed 
with Par6, phospho-aPKC Thr410/403, and aPKC antibodies. (C) Expression of the indicated 
genes in EGF-treated U251/EGFR cells transfected with aPKC, Par6, or p62 siRNAs, as 
determined by RT-qPCR. Expression was normalized to control U251/EGFR cells. (D) 
Expression of the indicated genes in TNFα-treated U251/EGFR cells transfected with 
aPKC, Par6, or p62 siRNAs, as determined by RT-qPCR. Expression was normalized to 
control U251/EGFR cells. (E) Representative images showing the colocalization of aPKC 
and Par6 with phalloidin at lamellipodia in EGF-stimulated U251/EGFR cells (white arrows, 
left and middle panels) and the colocalization of aPKC and p62 in the intracellular 
compartment in TNFα-treated U251/EGFR cells (gray arrow, right panel). Some aPKC was 
detectable at the lamellipodia of the cells (white arrow). Scale bar, 10 μm. (F) Expression of 
the indicated genes in U251 cells transfected with myr-aPKCζ, as determined by RT-qPCR. 
Expression was normalized to the mRNA abundance in untransfected U251 cells. Data for 
(A) to (F) are presented as representative images or as means ± SEM of at least three 
independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001; ns, nonsignificant.
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Fig. 7. Schematic illustrating aPKC-containing signaling complexes in cell-autonomous RTK and 
non–cell-autonomous TNFα–NF-κB oncogenic signaling in glioblastoma
EGFR and/or other oncogenic RTK signaling pathways within the glioblastoma cell activate 
aPKC in a Par6-dependent fashion and lead to the expression of oncogenic genes. In 
parallel, TNFα produced by macrophages in the tumor microenvironment activates aPKC in 
a p62-dependent manner. This activation leads to the expression of NF-κB–dependent 
genes, which function as EGFR-independent oncogenic signals in glioblastoma.
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